Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation

MALČÍKOVÁ, Jitka, Jana KOTAŠKOVÁ, Šárka PAVLOVÁ, Nikola TOM, Karol PÁL, Anna PANOVSKÁ, Yvona BRYCHTOVÁ, Michael DOUBEK and Šárka POSPÍŠILOVÁ. Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation. In XVII International Workshop on Chronic Lymphocytic Leukemia. 2017.

Basic information

• Original name: Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation
• Authors: MALČÍKOVÁ, Jitka (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), Karol PÁL (703 Slovakia, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution).
• Edition: XVII International Workshop on Chronic Lymphocytic Leukemia, 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 10606 Microbiology
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14740/17:00095698
• Organization unit: Central European Institute of Technology
• Keywords in English: TP53; CLL; subclones
• Tags: rivok

Abstract

Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation, Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1106/2016, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

• NV15-29793A, research and development project: Name: Analýza Wnt/PCP jako nástroj pro lepší management chronické lymfocytární leukémie
• NV15-31834A, research and development project: Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie
• 692298, interní kód MU: Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)

Investor: European Union, Spreading excellence and widening participation